Trials / Completed
CompletedNCT06336512
Trimester Sequential Estimation of Serum Zonulin as a Predictor of Gestational Diabetes Mellitus
Trimester Sequential Estimation of Serum Zonulin Overrides Glucose Homeostasis Biomarkers for Prediction of Gestational Diabetes Mellitus
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- Female
- Age
- 22 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Gestational diabetes mellitus (GDM) is the development of glucose intolerance (GI) during pregnancy in a previously normoglycemic (NG) woman and associated with insulin resistance (IR). GDM is the most prevalent metabolic disorder during pregnancy and became a major public health problem for being usually diagnosed and detected after 24 gestational weeks (GW), while its complications can occur much earlier and this may explain its burden on maternal and fetal welfare. Human zonulin is a surrogate marker of intestinal permeability and can be utilized as biomarker for intestinal barrier function. Zonulin-mediated increase in intestinal permeability plays a role in the pathogenesis of insulin resistance, obesity, DM and metabolic syndrome. The increasing global prevalence of GDM with its associated risk of poor pregnancy and long-term risks for the mother and the offspring may lead to the production of new generation of diabetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ELISA | Estimation of Zonulin by ELISA from the Blood samples which were obtained at time of pregnancy . |
Timeline
- Start date
- 2023-01-15
- Primary completion
- 2023-07-01
- Completion
- 2023-10-01
- First posted
- 2024-03-28
- Last updated
- 2024-03-28
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06336512. Inclusion in this directory is not an endorsement.